CRO

Big Health System Deals Dominate Transactions in October-The announced merger of two major Texas health systems is October’s deal-of-the-month.

What to Expect in a Due Diligence Process – Episode 7 of Provident’s Healthcare Dealcast

INSIGHT: Long-Term Care Consolidations Lead Third Quarter Health Transactions – The breakneck pace of healthcare transactions continued unabated in the third quarter.

What are the key financial factors to focus on when undergoing a process?– Episode 6 of Provident’s Healthcare Dealcast

Q3-2018 CRO Update – While the previous four quarters had been defined by super mergers and strategic consolidation, the third quarter of 2018 saw a resurgence of private equity investment into the contract research space.

Private Equity Investment in Health Care Stays Strong – Private equity investment is burgeoning throughout the U.S., and health care is one of the “in” targets for investors.

Health IT Sector Showing High Potential for Accelerated Growth – The health information technology sector is poised to become the next big thing for investors in the health-care industry. The physician practices sector experienced the second-highest growth in July, with an emphasis on certain medical practice areas.

INSIGHT: Strong Health-Care Deal Activity Seen in 2018’s First Half– The first half of 2018 saw a strong wave of M&A and deal making activity across nearly all sectors of the U.S. healthcare industry. The second half of 2018 likely will be just as robust.

What Types of Transactions Could be Right for my Healthcare Services Business?– Episode 3 of Provident’s Healthcare Dealcast

What are the Benefits of Hiring an Investment Banking Firm?– Episode 2 of Provident’s Healthcare Dealcast

Why Is Healthcare Consolidating?– Episode 1 of Provident’s Healthcare Dealcast

Q2-2018 CRO Update-The world’s three largest providers of contract research services (Quintiles, LabCorp, and PPD) control nearly 50% of the global revenue in the industry.

Q1-2018 CRO Update– Improving productivity and efficiency in clinical development processes will continue to be the main industry growth driver for 2018. As sponsors look to find ways to improve cycle time and reduce costs, contract research organizations that are able to provide risk based monitoring, adaptive trial designs, and flexible delivery models will see increased interest.

Amazon Deal Brightens Blasé January Health Transactions Landscape – The late January announcement that Amazon.com Inc., BerkshireHathaway Inc., and JPMorgan Chase & Co. plan to join forces to meet their employees’ health-care needs created a lot of health-care industry dealmaking buzz in a month that was otherwise on the quiet side.

Q4-2017 CRO Update– The overall contract research market pulled back a bit in the fourth quarter of 2017. As many of the industry giants spent most of 2017 making large acquisitions, the final months saw mid-sized players make aggressive moves to broaden service lines.

Q3-2017 CRO Update– The current state of the contract research organization industry continues to be largely shaped by the super mergers of the past. The landscape for mid-sized CRO’s has drastically changed as the revenue gap has widened between mega-CRO’s and the rest of the industry.

Annual Healthcare and Life Sciences Private Equity and Finance Conference – Steven Aguiar will be attending the 16th Annual Healthcare and Life Sciences Private Equity and Finance Conference February 20-21 in Chicago.

Top Trends in the Contract Research Organization Industry– In this Provident Perspective, we will discuss our thoughts on the main trends driving the contract research industry. Through discussions with industry executives, private equity groups, and proprietary research, we have established a list of eight definitive insights into the space and how they are affecting the current M&A marketplace.

Transaction Advisory – Willow Laboratories announced today that it has been acquired by Ampersand Capital Partners. Willow is one of the country’s leading clinical and forensic toxicology laboratories providing urine, hair and saliva testing services to a wide range of healthcare providers including treatment centers, physician practices and other laboratories.

  • “While the decision to sell our business was a difficult one, Provident vigilantly represented and protected our best interests throughout the transaction.  Provident was the right choice for Cascade and I would recommend their services to anyone.”

  • “Provident’s depth of experience and practical business savvy was demonstrated in their ability to cut through what sometimes looked like impasse.”

  • ”I have a tremendous amount of appreciation and gratitude to the Provident team for their hard work and diligence throughout this process. Each and every member of the Provident team is excellent at their jobs and it has been a pleasure working with such a professional team. Provident has provided outstanding guidance and counsel, and this deal could never have gotten done without Provident’s leadership.”

  • “Provident listened to our story, confirmed that our business was valuable and made us feel like this was the only transaction important to them.”

  • “We would not have been successful navigating the process without Provident’s hard work and active participation. They exceeded our expectations and we would highly recommend them to any health care company seeking a knowledgeable and engaged investment banking firm.”

  • “A lot of investment bankers were interviewed, Provident was chosen. Provident delivered. My clients could not be happier.”

  • “After working with Provident on several transactions, it is evident that their extensive industry knowledge and deal expertise prove to be invaluable to their clients.”